Increased albuminuria in bardoxolone methyl-treated type 2 diabetes patients: mere reflection of eGFR improvement?
Bardoxolone methyl activates nuclear factor erythroid 2-related factor 2 and increases glomerular filtration rate in patients with diabetic kidney disease. Because bardoxolone methyl also increases albuminuria, Rossing and colleagues performed a retrospective analysis of the Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes (BEACON) study and attributed increased albuminuria to increased estimated glomerular filtration rate. Although the study emphasizes bardoxolone methyl's benefits in diabetic kidney disease, we must be careful about interpretation.